Article

Aflibercept filed in Japan

Regeneron PharmaceuticalsInc. and Bayer HealthCare have announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to Japan?s Ministry of Health, Labor and Welfare (MHLW) for marketing authorization of aflibercept ophthalmic solution (VEGF Trap-Eye) for the treatment of the neovascular form of age-related macular degeneration (AMD)

Tarrytown, NY, and Berlin, Germany-Regeneron Pharmaceuticals Inc. and Bayer HealthCare have announced that Bayer Yakuhin Ltd., Osaka, Japan, has submitted an application to Japan’s Ministry of Health, Labor, and Welfare (MHLW) for marketing authorization of aflibercept ophthalmic solution (VEGF Trap-Eye) for the treatment of the neovascular form of age-related macular degeneration (AMD).

The submission to MHLW is based on the positive results from two phase III trials:  the VIEW 1 study conducted in North America, and the VIEW 2 study conducted in Japan, Europe, and other countries.
Aflibercept was submitted for marketing approval for the treatment of wet AMD in the United States in February 2011 by Regeneron, and in Europe in June 2011 by Bayer HealthCare.

Regeneron and Bayer HealthCare are collaborating on the global development of aflibercept for the treatment of wet AMD, central retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization. Bayer HealthCare will market aflibercept outside the United States, while Regeneron maintains exclusive marketing rights in the United States.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.